Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly

NCT00492063 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2654

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Cell culture-derived trivalent subunit influenza vaccine (cTIV)
BIOLOGICAL: Egg-derived trivalent subunit influenza vaccine (TIV)

Sponsor

Novartis Vaccines